The Neurofibromatosis type 1:A dominantly inherited tumors-predisposing disorder

[1] Friedman J.M., Riccardi V.M., Neurofibromatosis: phenotype, natural history and pathogenesis, 3rd ed., Baltimore, Johns Hopkins University Press, 1999 Search in Google Scholar

[2] Riccardi V.M., Lewis R.A., Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendant, Am. J. Hum. Genet., 1988, 42, 284–289 Search in Google Scholar

[3] Szudek J., Joe K., Friendman J.M., Analysis of Intrafamilial Phenotype Variation in Neurofibromatosis 1 (NF1), Genet. Epidem., 2002, 23, 150–164 http://dx.doi.org/10.1002/gepi.112910.1002/gepi.1129Search in Google Scholar

[4] Wallace M.R., Marchuk D.A., Andersen L.B., Letcher R., Odeh H.M., Saulino A.M., et al., Type 1 neurofibromatosis gene: identification of a larger transcript disrupted in three NG1 patients, Science, 1990, 249, 181–186 http://dx.doi.org/10.1126/science.213473410.1126/science.2134734Search in Google Scholar

[5] Xu G.F., O’Connell P., Viskochil D., Cawthon R., Robertson M., Culver M., et al., The neurofibromatosis type 1 gene encodes a protein related to GAP, Cell, 1990, 62, 599–608 http://dx.doi.org/10.1016/0092-8674(90)90024-910.1016/0092-8674(90)90024-9Search in Google Scholar

[6] Walzer L., Thompson D., Ponder B.M., Frayling I., Baralle D., A prospective study of neurofibromatosis type I cancer incidence in the UK, Brit. J. Cancer, 2006, 95, 233–238 http://dx.doi.org/10.1038/sj.bjc.660322710.1038/sj.bjc.6603227Search in Google Scholar

[7] Zoller M.E., Rembeck B., Oden A., Samuelsson M., Angervall L., Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population, Cancer, 1997, 79, 2125–2133 http://dx.doi.org/10.1002/(SICI)1097-0142(19970601)79:11<2125::AID-CNCR9>3.0.CO;2-N10.1002/(SICI)1097-0142(19970601)79:11<2125::AID-CNCR9>3.0.CO;2-NSearch in Google Scholar

[8] National Institutes of Health Consensus Development Conference Statement, Neurofibromatosis, Arch. Neurol. (Chicago), 1988, 45, 575–578 10.1001/archneur.1988.00520290115023Search in Google Scholar

[9] Ward B.A., Gutmann D.H., Neurofibromatosis 1: from lab bench to clinic, Pediatr. Neurol., 2005, 32, 221–228 http://dx.doi.org/10.1016/j.pediatrneurol.2004.11.00210.1016/j.pediatrneurol.2004.11.002Search in Google Scholar

[10] Tonsgard J.H., Clinical manifestations and management of neurofibromatosis type 1, Semin. Pediatr. Neurol., 2006, 13, 2–7 http://dx.doi.org/10.1016/j.spen.2006.01.00510.1016/j.spen.2006.01.005Search in Google Scholar

[11] Messiaen L.M., Callens T., Mortier G., Beysen D., Vandenbroucke I., Van Roy N., et al., Exhaustive mutation analysis of the Nf1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects, Hum. Mutat., 2000, 15, 541–555 http://dx.doi.org/10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-NSearch in Google Scholar

[12] Jentarra G., Snyder S.L., Narayanan V., Genetic aspects of neurocutaneous disorders, Semin. Pediatr. Neurol., 2006, 13, 43–47 http://dx.doi.org/10.1016/j.spen.2006.01.01010.1016/j.spen.2006.01.010Search in Google Scholar

[13] Gutmann D.H., Wood D.L., Collins F.S., Identification of the neurofibromatosis type 1 gene product, Proc. Natl. Acad. Sci. USA, 1991, 88, 9658–9662 http://dx.doi.org/10.1073/pnas.88.21.965810.1073/pnas.88.21.9658Search in Google Scholar

[14] Daston M.M., Scrable H., Nordlund M., Sturbaum AK., Nissen L.M., Ratner N., The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes, Neuron., 1992, 8, 415–428 http://dx.doi.org/10.1016/0896-6273(92)90270-N10.1016/0896-6273(92)90270-NSearch in Google Scholar

[15] Castle B., Baser M.E., Huson S.M., Cooper D.N., Upadhyaya M., Evaluation of genotype-phenotype correlations in neurofibromatosis type 1, J. Med. Genet., 2003, 40, 109 http://dx.doi.org/10.1136/jmg.40.10.e10910.1136/jmg.40.10.e109Search in Google Scholar

[16] Trovo-Marqui A.B., Tajara E.H., Neurofibromin: a general outlook. Clin. Genet., 2006, 70, 1–13 http://dx.doi.org/10.1111/j.1399-0004.2006.00639.x10.1111/j.1399-0004.2006.00639.xSearch in Google Scholar

[17] Weiss B., Bollag G., Shannon K., Hyperactive Ras as a therapeutic target in neurofibromatosis type 1, Am. J. Med. Genet., 1999, 89, 14–22 10.1002/(SICI)1096-8628(19990326)89:1<14::AID-AJMG5>3.0.CO;2-4Search in Google Scholar

[18] Rasmussen S.A., Overman J., Thomson S.A., Colman S.D., Abernathy C.R., Trimpert R.E., et al., Chromosome 17 loss of heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1, Genes Chromosomes Cancer, 2000, 28, 425–31 http://dx.doi.org/10.1002/1098-2264(200008)28:4<425::AID-GCC8>3.0.CO;2-E10.1002/1098-2264(200008)28:4<425::AID-GCC8>3.0.CO;2-ESearch in Google Scholar

[19] Sawada S., Florell S., Purandare S.M., Ota M., Stephens K., Viskochil D., Identification of NF1 mutations in both alleles of a dermal Neurofibroma, Nat. Genet., 1996, 14, 110–112 http://dx.doi.org/10.1038/ng0996-11010.1038/ng0996-110Search in Google Scholar

[20] Korf B., Malignancy in neurofibromatosis type 1, Oncologist, 2000, 5, 477–485 http://dx.doi.org/10.1634/theoncologist.5-6-47710.1634/theoncologist.5-6-477Search in Google Scholar

[21] Zhu Y., Parada L.F., The molecular and genetic basis of neurological tumours, Nat. Rev. Cancer, 2002, 2, 616–626 http://dx.doi.org/10.1038/nrc86610.1038/nrc866Search in Google Scholar

[22] Castle B., Baser M.E., Huson S.M., Cooper D.N., Upadhyaya M., Evaluation of genotype-phenotype correlations in neurofibromatosis type 1, J. Med. Genet., 2003, 40, 109 http://dx.doi.org/10.1136/jmg.40.10.e10910.1136/jmg.40.10.e109Search in Google Scholar

[23] Levy P., Vidaud D., Leroy K., Laurendeau I., Wechsler J., Bolasco G., et al., Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR, Mol. Cancer, 2004, 3, 20 http://dx.doi.org/10.1186/1476-4598-3-2010.1186/1476-4598-3-20Search in Google Scholar

[24] Shearer P., Parham D., Kovnar E., Kun L., Rao B., Lobe T., et al., Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution, Med. Pediatr. Oncol., 1994, 22, 78–83 http://dx.doi.org/10.1002/mpo.295022020310.1002/mpo.2950220203Search in Google Scholar

[25] Glover T.W., Stein C.K., Legius E., Andersen L.B., Brereton A., Johnson S., Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis, Genes Chromosomes Cancer, 1991, 3, 62–70 http://dx.doi.org/10.1002/gcc.287003011110.1002/gcc.2870030111Search in Google Scholar

[26] Li Y., O’Connel P., Breidenbach H.H., Cawthon R., Stevens J., Xu G., et al., Genomic organization of the neurofibromatosis 1 gene (NF1), Genomics, 1995, 25, 918 http://dx.doi.org/10.1016/0888-7543(95)80104-T10.1016/0888-7543(95)80104-TSearch in Google Scholar

[27] Korf B., Malignancy in neurofibromatosis type 1, Oncologist, 2000, 5, 477–485 http://dx.doi.org/10.1634/theoncologist.5-6-47710.1634/theoncologist.5-6-477Search in Google Scholar PubMed

[28] Kimura M., Kamata Y., Matsumoto K., Takaya H., Electron microscopical study on the tumour of von Recklinghausen’s neurofibromatosis. Acta. Pathol. Jpn., 1974, 24, 79–91 10.1111/j.1440-1827.1974.tb00809.xSearch in Google Scholar PubMed

[29] Tonsgard J.H., Kwak S.M., Short M.P., Dachman A.H., CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions, Neurology, 1998, 50, 1755–1760 10.1212/WNL.50.6.1755Search in Google Scholar

[30] Lott I.T., Richardson E.P., Neuropathologic findingsand the biology of neurofibromatosis, Adv. Neuron., 1981, 29, 23–32 Search in Google Scholar

[31] Ferner R.E., Neurofibromatosis 1, Eur. J. Hum. Genet., 2007, 15, 131–8 http://dx.doi.org/10.1038/sj.ejhg.520167610.1038/sj.ejhg.5201676Search in Google Scholar PubMed

[32] DeBella K., Szudek J., Friedman J.M., Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children, Pediatrics, 2000, 105, 608–614 http://dx.doi.org/10.1542/peds.105.3.60810.1542/peds.105.3.608Search in Google Scholar PubMed

[33] Evans D.G., Baser M.E., Mc Gaughran J., Sharif S., Howard E., Moran A., Malignant peripheral nerve sheath tumours in neurofibromatosis 1, J. Med. Genet., 2002, 39, 311–314 http://dx.doi.org/10.1136/jmg.39.5.31110.1136/jmg.39.5.311Search in Google Scholar PubMed PubMed Central

[34] Carli M., Ferrari A., Mattke A., Zanetti I., Casanova M., Bisogno G., et al., Pediatric malignant peripheral nerve sheath tumor: the Italian and German Soft Tissue Sarcoma Cooperative Group, J. Clin. Oncol., 2005, 23, 8422–8430 http://dx.doi.org/10.1200/JCO.2005.01.488610.1200/JCO.2005.01.4886Search in Google Scholar

[35] Lakkis M.M., Tennekoon G.I., Neurofibromatosis type1. I. General overview, J. Neurosci. Res., 2000, 62, 755–763 http://dx.doi.org/10.1002/1097-4547(20001215)62:6<755::AID-JNR1>3.0.CO;2-W10.1002/1097-4547(20001215)62:6<755::AID-JNR1>3.0.CO;2-WSearch in Google Scholar

[36] Guha A., Lau N., Huvar I., Gutmann D., Provias J., Pawson T., et al., RAS-GTP levels are elevated in human peripheral nerve tumours, Oncogene, 1996, 12, 507–513 Search in Google Scholar

[37] Wu R., Lopez-Correa C., Rutkowski J.L., Baumbach L.L., Glover T.W., Legius E., Germline mutations in NF1 patients with malignancies, Genes Chromosomes Cancer, 1999, 26, 376–380 http://dx.doi.org/10.1002/(SICI)1098-2264(199912)26:4<376::AID-GCC13>3.0.CO;2-O10.1002/(SICI)1098-2264(199912)26:4<376::AID-GCC13>3.0.CO;2-OSearch in Google Scholar

[38] Birindelli A., Perrone F., Oggionni M., Lavarino C., Pasini B., Vergani B., et al. Pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumours, Lab. Invest., 2001, 81, 833–844 10.1038/labinvest.3780293Search in Google Scholar

[39] De Raedt T., Brems H., Wolkenstein P, Vidaud D., Pilotti S., Perrone F., et al., Elevated risk for MPNST in NF1 microdeletion patient, Am. J. Hum. Genet., 2003, 72, 1288–1292 http://dx.doi.org/10.1086/37482110.1086/374821Search in Google Scholar

[40] Perrone F., Tabano S., Colombo F., Dagrada G., Birindelli S., Gronchi A., et al., p15INK4b, p14ARF and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumours, Clin. Cancer Res., 2003, 9, 4132–4138 Search in Google Scholar

[41] Listernick R., Charrow J., Greenwald M., Mets M., Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study, J. Pediatr., 1994, 125, 63–66 http://dx.doi.org/10.1016/S0022-3476(94)70122-910.1016/S0022-3476(94)70122-9Search in Google Scholar

[42] Listernick R., Louis D.N., Packer R.J., Gutmann D.H, Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force, Ann. Neurol., 1997, 41, 143–149 http://dx.doi.org/10.1002/ana.41041020410.1002/ana.410410204Search in Google Scholar

[43] Arun D., Gutmann D.H., Recent advances in neurofibromatosis type 1, Curr. Opin. Neuro., 2004, 7, 101–105 http://dx.doi.org/10.1097/00019052-200404000-0000410.1097/00019052-200404000-00004Search in Google Scholar

[44] Singhal S., Birch J.M., Kerr B., Lashford L., Evans D.G., Neurofibromatosis type 1 and sporadic optic gliomas. Arch. Dis. Child., 2002, 87. 65–70 http://dx.doi.org/10.1136/adc.87.1.6510.1136/adc.87.1.65Search in Google Scholar

[45] Thiagalingam S., Flaherty M., Billson F., North K., Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients, Ophthalmology, 2004, 111, 568–577 http://dx.doi.org/10.1016/j.ophtha.2003.06.00810.1016/j.ophtha.2003.06.008Search in Google Scholar

[46] Dasgupta B., Yi Y., Chen D.Y., Weber J.D., Gutmann D.H., Proteomic analysis reveals hyper-activation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumours, Cancer Res., 2005, 1, 2755–2760 http://dx.doi.org/10.1158/0008-5472.CAN-04-405810.1158/0008-5472.CAN-04-4058Search in Google Scholar

[47] Zhu Y., Harada T., Liu L., Lush M.E., Guignard F., Harada C., et al., Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation, Development, 2005, 132, 5577–5588 http://dx.doi.org/10.1242/dev.0216210.1242/dev.02162Search in Google Scholar

[48] Sung L., Anderson J.R., Arndt C., Raney R.B., Meyer W.H., Pappo A.S., Neurofibromatosis in children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study IV, J. Pediatr., 2004, 144, 666–668 http://dx.doi.org/10.1016/j.jpeds.2004.02.02610.1016/j.jpeds.2004.02.026Search in Google Scholar

[49] Reich S., Overberg-Schmidt S.O., Leenen A., Henze G., Neurofibromatosis 1 associated with embryonal rhabdomyosarcoma of the urinary bladder, Pediatric. Hematol. Oncol., 1999, 16, 263–266 http://dx.doi.org/10.1080/08880019927733510.1080/088800199277335Search in Google Scholar

[50] Lampe A.K., Seymour G., Thompson P.W., Toutain A., Lynch S.A., Familial neurofibromatosis microdeletion syndrome complicated by rhabdomyosarcoma. Arch. Dis. Child., 2002, 87, 444–445 http://dx.doi.org/10.1136/adc.87.5.44410.1136/adc.87.5.444Search in Google Scholar

[51] Jang K.A., Choi J.H., Sung K.J., Moon K.C., Koh J.K., Im D.J., Juvenile chronic myelogenous leukemia, neurofibromatosis 1, and xanthoma, J. Dermatol., 1999, 26, 33–35 10.1111/j.1346-8138.1999.tb03506.xSearch in Google Scholar

[52] Benessahraoui M., Aubin F., Paratte F., et al., Juvenile myelomonocytic leukaemia, xanthoma, and neurofibromatosis type 1, Arch. Pediatr., 2003, 10, 891–894. http://dx.doi.org/10.1016/S0929-693X(03)00456-110.1016/S0929-693X(03)00456-1Search in Google Scholar